Resminostat
- Generic Name
- Resminostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O4S
- CAS Number
- 864814-88-0
- Unique Ingredient Identifier
- 1578EUB98L
- Background
Resminostat has been used in trials studying the treatment of Sezary Syndrome, Mycosis fungoides, Hodgkin's Lymphoma, Hepatocellular Carcinoma, and Lymphoma, T-Cell, Cutaneous, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 201
- Registration Number
- NCT02953301
- Locations
- 🇯🇵
Okayama University Hospital, Okayama, Japan
🇵🇱Uniwersytecki Szpital Kliniczny im. WAM - CSW, Łódź, Poland
🇬🇷ATTIKON Hospital and Cutaneous Lymphoma Clinic, Athens, Greece
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 179
- Registration Number
- NCT02400788
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath